Clinical Pharmacology (CPSR - A439)
The major CP services are in four domains:
1a: Development of novel analyte assays using either LC-MS/MS or LC-UV/FLD detection methods
1b: Performance of analyte-concentration measurements in biospecimens from preclinical and clinical oncology studies using these validated bioanalytical assays
1c: Measurement of pharmacodynamic endpoints including western blotting and a new cellular cytotoxicity service
2a: Expert consultation regarding study design and pharmacokinetic (PK) and pharmacodynamic (PD) hypothesis-development and testing in preclinical and clinical cancer studies
2b: PK and PD data analysis and PK-PD modeling
3: Central proessing for biospecimens (e.g. cells, tumor tissue, plasma, saliva, urine, DNA) obtained as part of approved clinical and epidemiological protocols. Services include sample logging, processing, aliquoting, storage, and sample distribution when necessary
4 Research pharmacy services for cancer therapeutic clinical studies with both commercially available drugs and drugs under investigational new drug application
Please contact us for new projects prior to ordering any service (except SpectraMax i3x use) - consultation is free and necessary.
Lionel.D.Lewis@dartmouth.edu or Dylan.B.Ness@hitchcock.org
Use of any of the Shared Resource services or instrumentation needs to be acknowledged in any publications or presentations along with NCI Cancer Center Support Grant 5P30CA023108-37.
